AP-1 confers resistance to anti-cancer therapy by activating XIAP
The underlying cause of treatment failure in many cancer patients is intrinsic and acquired resistance to chemotherapy. Recently, histone deacetylase (HDAC) inhibitors have developed into a promising cancer treatment. However, resistance mechanism induced by HDAC inhibitors remains largely unknown....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865658/ https://www.ncbi.nlm.nih.gov/pubmed/29581832 http://dx.doi.org/10.18632/oncotarget.23897 |
_version_ | 1783308714038525952 |
---|---|
author | Wang, Yuan Wan, Guo-Hui Wu, Ying-Min Wang, Hong-Sheng Wang, Hai-Fang Zhang, Ge Lu, Lin-Lin Li, Zi-Qian Chan, Ka-Ying Zhou, Yan Cai, Shao-Hui Qi, Yi-Fei Du, Jun |
author_facet | Wang, Yuan Wan, Guo-Hui Wu, Ying-Min Wang, Hong-Sheng Wang, Hai-Fang Zhang, Ge Lu, Lin-Lin Li, Zi-Qian Chan, Ka-Ying Zhou, Yan Cai, Shao-Hui Qi, Yi-Fei Du, Jun |
author_sort | Wang, Yuan |
collection | PubMed |
description | The underlying cause of treatment failure in many cancer patients is intrinsic and acquired resistance to chemotherapy. Recently, histone deacetylase (HDAC) inhibitors have developed into a promising cancer treatment. However, resistance mechanism induced by HDAC inhibitors remains largely unknown. Here we report that a HDAC inhibitor, JNJ-2648158 induced transcription of XIAP by activating AP-1 expression, which conferring resistance to chemotherapeutics. Our results showed that high expression of c-Fos caused by HDAC inhibitor promoted AP-1 formation during acquired resistance towards chemo-drugs, indicating an extremely poor clinical outcome in breast cancers and liver cancers. Our study reveals a novel regulatory mechanism towards chemo-drug resistance, and suggests that XIAP may serve as a potential therapeutic target in those chemo-resistant cancer cells. |
format | Online Article Text |
id | pubmed-5865658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58656582018-03-26 AP-1 confers resistance to anti-cancer therapy by activating XIAP Wang, Yuan Wan, Guo-Hui Wu, Ying-Min Wang, Hong-Sheng Wang, Hai-Fang Zhang, Ge Lu, Lin-Lin Li, Zi-Qian Chan, Ka-Ying Zhou, Yan Cai, Shao-Hui Qi, Yi-Fei Du, Jun Oncotarget Research Paper The underlying cause of treatment failure in many cancer patients is intrinsic and acquired resistance to chemotherapy. Recently, histone deacetylase (HDAC) inhibitors have developed into a promising cancer treatment. However, resistance mechanism induced by HDAC inhibitors remains largely unknown. Here we report that a HDAC inhibitor, JNJ-2648158 induced transcription of XIAP by activating AP-1 expression, which conferring resistance to chemotherapeutics. Our results showed that high expression of c-Fos caused by HDAC inhibitor promoted AP-1 formation during acquired resistance towards chemo-drugs, indicating an extremely poor clinical outcome in breast cancers and liver cancers. Our study reveals a novel regulatory mechanism towards chemo-drug resistance, and suggests that XIAP may serve as a potential therapeutic target in those chemo-resistant cancer cells. Impact Journals LLC 2018-01-03 /pmc/articles/PMC5865658/ /pubmed/29581832 http://dx.doi.org/10.18632/oncotarget.23897 Text en Copyright: © 2018 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wang, Yuan Wan, Guo-Hui Wu, Ying-Min Wang, Hong-Sheng Wang, Hai-Fang Zhang, Ge Lu, Lin-Lin Li, Zi-Qian Chan, Ka-Ying Zhou, Yan Cai, Shao-Hui Qi, Yi-Fei Du, Jun AP-1 confers resistance to anti-cancer therapy by activating XIAP |
title | AP-1 confers resistance to anti-cancer therapy by activating XIAP |
title_full | AP-1 confers resistance to anti-cancer therapy by activating XIAP |
title_fullStr | AP-1 confers resistance to anti-cancer therapy by activating XIAP |
title_full_unstemmed | AP-1 confers resistance to anti-cancer therapy by activating XIAP |
title_short | AP-1 confers resistance to anti-cancer therapy by activating XIAP |
title_sort | ap-1 confers resistance to anti-cancer therapy by activating xiap |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865658/ https://www.ncbi.nlm.nih.gov/pubmed/29581832 http://dx.doi.org/10.18632/oncotarget.23897 |
work_keys_str_mv | AT wangyuan ap1confersresistancetoanticancertherapybyactivatingxiap AT wanguohui ap1confersresistancetoanticancertherapybyactivatingxiap AT wuyingmin ap1confersresistancetoanticancertherapybyactivatingxiap AT wanghongsheng ap1confersresistancetoanticancertherapybyactivatingxiap AT wanghaifang ap1confersresistancetoanticancertherapybyactivatingxiap AT zhangge ap1confersresistancetoanticancertherapybyactivatingxiap AT lulinlin ap1confersresistancetoanticancertherapybyactivatingxiap AT liziqian ap1confersresistancetoanticancertherapybyactivatingxiap AT chankaying ap1confersresistancetoanticancertherapybyactivatingxiap AT zhouyan ap1confersresistancetoanticancertherapybyactivatingxiap AT caishaohui ap1confersresistancetoanticancertherapybyactivatingxiap AT qiyifei ap1confersresistancetoanticancertherapybyactivatingxiap AT dujun ap1confersresistancetoanticancertherapybyactivatingxiap |